Evolution Advisers’s Bristol-Myers Squibb BMY Stock Holding History

Evolution Advisers’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$0	Buy	+8	New	+$459	﹤0.01%	298
2023 Q4	–	Sell	-180	Closed	-$10K	–	215
2023 Q3	$10K	Hold	180	–	–	0.01%	106
2023 Q2	$11K	Hold	180	–	–	0.01%	110
2023 Q1	$12K	Hold	180	–	–	0.01%	105
2022 Q4	$12K	Hold	180	–	–	0.01%	114
2022 Q3	$12K	Sell	180 -220	-55%	-$16K	0.01%	100
2022 Q2	$30K	Hold	400	–	–	0.02%	80
2022 Q1	$29K	Buy	+400	New	+$26.9K	0.02%	83

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Evolution Advisers's BMY Position: Q2 2026 in Review

Evolution Advisers opened a new position in Bristol-Myers Squibb (BMY) in Q2 2026: 8 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #298 among its holdings. This is a return to the name: Evolution Advisers previously reported a position in BMY as recently as Q3 2023.

Evolution Advisers first reported a position in BMY in Q1 2022 and has held it in 8 quarters since. The position peaked at $30K in Q2 2022. 2,523 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Evolution Advisers held 8 shares of Bristol-Myers Squibb worth $0 as of Q2 2026.
Bristol-Myers Squibb was a new Evolution Advisers position in Q2 2026.
Bristol-Myers Squibb made up ﹤0.01% of Evolution Advisers's portfolio in Q2 2026, its #298 holding.
Evolution Advisers first reported a position in Bristol-Myers Squibb in Q1 2022 and has held it in 8 quarters since.
Evolution Advisers's Bristol-Myers Squibb position peaked at $30K in Q2 2022.
2,523 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Evolution Advisers's 13F filing for Q2 2026, filed 31 Jul 2026.